Table 2.
Number of markers correlated to disease stage.
| AJCC stage, n (%) | ||||||
|---|---|---|---|---|---|---|
| Markers | ||||||
| detected, | I | II | III | IV | Total | |
| n | (n = 20) | (n = 20) | (n = 32) | (n = 22) | (n = 94) | P |
| 0 | 17 (85) | 14 (70) | 8 (25) | 3 (14) | 42 (45) | <0.0001a |
| 1 | 3 (15) | 3 (15) | 12 (37) | 7 (32) | 25 (26) | |
| 2 | 0 (0) | 3 (15) | 7 (22) | 8 (36) | 18 (19) | |
| 3 | 0 (0) | 0 (0) | 5 (16) | 3 (14) | 8 (9) | |
| 4 | 0 (0) | 0 (0) | 0 (0) | 1 (5) | 1 (1) | |
| ≤1 | 20 (100) | 17 (85) | 20 (63) | 10 (45) | 67 (71) | <0.0001b |
| ≥2 | 0 (0) | 3 (15) | 12 (37) | 12 (55) | 17 (29) | |
a
Spearman correlation coefficient analysis showed a significant correlation between number of positive markers and AJCC stage.
b
Cochran–Armitage trend test showed a significant increase of patients with more than 2 positive markers detected in advanced stage of disease.